Oncternal Therapeutics, Inc. (ONCT)
- Previous Close
8.21 - Open
8.00 - Bid --
- Ask --
- Day's Range
8.00 - 8.29 - 52 Week Range
5.57 - 13.20 - Volume
1,435 - Avg. Volume
8,346 - Market Cap (intraday)
24.535M - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-13.43 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.67
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
www.oncternal.comRecent News: ONCT
Performance Overview: ONCT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCT
Valuation Measures
Market Cap
24.54M
Enterprise Value
-9.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.23
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.48%
Return on Equity (ttm)
-86.75%
Revenue (ttm)
785k
Net Income Avi to Common (ttm)
-39.48M
Diluted EPS (ttm)
-13.43
Balance Sheet and Cash Flow
Total Cash (mrq)
34.26M
Total Debt/Equity (mrq)
1.06%
Levered Free Cash Flow (ttm)
-19.38M